BC Extra | Dec 4, 2017
Company News

Mustang, Harvard partner on CRISPR CAR T therapies

Mustang Bio Inc. (NASDAQ:MBIO) partnered with Harvard University to develop CRISPR-Cas9-enhanced CAR T therapies targeting hematologic and solid tumor cancers. The biotech in-licensed CRISPR-Cas9 gene editing technology from Harvard, as well as technology related to...
BC Extra | May 16, 2017
Clinical News

New technologies in focus at ASGCT

ToolGen Inc. (KONEX:199800), Editas Medicine Inc. (NASDAQ:EDIT) and Selecta Biosciences Inc. (NASDAQ:SELB) each spotlighted new technologies and techniques at the American Society for Gene and Cell Therapy (ASGCT) meeting in Washington, D.C. ToolGen Inc. showed...
Items per page:
1 - 2 of 2